Latest News for: mss

Edit

Photo Gallery Visit by Ms Koh Li-Na, Director-General of Meteorological Service Singapore (MSS) (28 November 2025) (JMA - Japan Meteorological Agency)

Public Technologies 23 Dec 2025
Koh Li-Na, Director-General of Meteorological Service Singapore (MSS), and an MSS delegation visited the Japan Meteorological Agency (JMA) and met with the Director-General NOMURA Ryoichi.
Edit

Welsh Labour MSs accuse Sir Keir Starmer of rolling back devolution

BBC News 03 Dec 2025
A letter criticised a programme to fund Welsh councils which bypasses ministers in Cardiff. .
Edit

Welsh Labour MSs accuse Starmer of rolling back devolution

BBC News 03 Dec 2025
A letter criticised a programme to fund Welsh councils which bypasses ministers in Cardiff ... .
Edit

Welsh Labour MSs accuse Starmer government of rolling back devolution

The Guardian 03 Dec 2025
Eleven Labour Senedd members (MSs) wrote to the prime minister and Labour leader claiming his ...
Edit

Managed Security Services (MSS) Market Review and Opportunities Assessment 2021-2030 - Cyber Threats Fuel Double-Digit Growth

Nasdaq Globe Newswire 27 Nov 2025
Key market opportunities for MSS include addressing the shortage of cybersecurity professionals, leveraging rapid growth in ...
Edit

Analyst Highlights Interesting Dogecoin Double Top Adam & Eve Pattern

NewsBTC 14 Nov 2025
Dogecoin Price Risks Drop To $0.16 With Double Top Adam And Eve Pattern ... He noted that DOGE remains under strong bearish pressure, following multiple Breaks of Structure (BOS) and Market Structure (MSS) on the 3-hour timeframe ... .
Edit

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines (Bicara Therapeutics Inc)

Public Technologies 08 Nov 2025
) Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines ... MSS tumors and 50% are KRAS WT ... MSS ... MSS.
Edit

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and ...

Nasdaq Globe Newswire 07 Nov 2025
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) ... .
Edit

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS

The Eagle-Tribune 07 Nov 2025
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) ... .
Edit

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) (Form 8-K) (Xilio Therapeutics Inc)

Public Technologies 07 Nov 2025
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB). Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need.
×